Study of the effectiveness of the response and interferon combination therapy for ribavirin monotherapy for chronic hepatitis C

Study of the effectiveness of the response and interferon combination therapy for ribavirin monotherapy for chronic hepatitis C - Study of the response of ribavirin monotherapy in patients with chronic hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017560

Enrollment

Registered

2015-05-14

Start date

2010-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

ribavirin monotherapy for 4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis patients with anti-HCV and HCV-RNA positive

Exclusion criteria

Exclusion criteria: We excluded: 1)HBs antibody positive 2))HIV antibody positive 3)decompensated liver chirrosis 4)severe herat failuer 5)severe kideny dysfunction 6)ineligible to interferon therapy

Design outcomes

Primary

Measure	Time frame
The effects of the combination therapy with interferon preceeded with ribavirin monotherapy.	—

Secondary

Measure	Time frame
Adverse events of ribavirin monotherapy.	—

Countries

Japan

Contacts

Public ContactTomoe Kobayashi

Hokkaido University Department of Gastroenterology

tk990063@yahoo.co.jp011-706-7429

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026